Late complications and survival of soft tissue sarcoma patients after adjuvant chemotherapy – a single tertiary centre experience

References

• Stiller CA, Trama A, Serraino D, The RARECARE Working Group., et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684–695. doi: 10.1016/j.ejca.2012.09.011.
   PubMed Web of Science ®Google Scholar
• Abaricia S, Van Tine BA. Management of localized extremity and retroperitoneal soft tissue sarcoma. Curr Probl Cancer. 2019;43(4):273–282. doi: 10.1016/j.currproblcancer.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–1365. doi: 10.1016/j.annonc.2021.07.006.
   PubMed Web of Science ®Google Scholar
• Casali PG. Adjuvant chemotherapy for soft tissue sarcoma. Am Soc Clin Oncol Educ Book. 2015;35:e629-33–e633. doi: 10.14694/EdBook_AM.2015.35.e629.
   Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–581. doi: 10.1002/cncr.23592.
   PubMed Web of Science ®Google Scholar
• Gustafson P, Åkerman M, Alvegård TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis—the SIN-system. Eur J Cancer. 2003;39(11):1568–1576. doi: 10.1016/s0959-8049(03)00369-1.
   PubMed Web of Science ®Google Scholar
• Shamai S, Rozenbaum Z, Merimsky O, et al. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry. BMC Cancer. 2020;20(1):609. doi: 10.1186/s12885-020-07104-9.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Eur Heart J. 2016;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211.
   PubMed Web of Science ®Google Scholar
• Tian Z, Yang Y, Yang Y, et al. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer. 2020;20(1):1139. doi: 10.1186/s12885-020-07663-x.
   PubMed Web of Science ®Google Scholar
• von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-lnduced congestive heart failure. Ann Intern Med. 1979;91(5):710–717. doi: 10.7326/0003-4819-91-5-710.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869–2879. doi: 10.1002/cncr.11407.
   PubMed Web of Science ®Google Scholar
• Kim YA, Cho H, Lee N, et al. Doxorubicin-induced heart failure in cancer patients: a cohort study based on the korean national health insurance database. Cancer Med. 2018;7(12):6084–6092. doi: 10.1002/cam4.1886.
   PubMed Web of Science ®Google Scholar
• Kongbundansuk S, Hundley WG. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. JACC Cardiovasc Imaging. 2014;7(8):824–838. doi: 10.1016/j.jcmg.2014.06.007.
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van Veldhuisen DJ, et al. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev. 2000;26(6):429–447. doi: 10.1053/ctrv.2000.0175.
   PubMed Web of Science ®Google Scholar
• Shantakumar S, Olsen M, Vo T, et al. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol. 2016;8:53–59. doi: 10.2147/CLEP.S100779.
   PubMed Web of Science ®Google Scholar
• Lee CH, Zhang JF, Yuan KSP, et al. Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old asian women with breast cancer. Strahlenther Onkol. 2019;195(7):629–639. doi: 10.1007/s00066-019-01428-7.
   PubMed Web of Science ®Google Scholar
• McGowan JW, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. doi: 10.1007/s10557-016-6711-0.
   PubMed Web of Science ®Google Scholar
• Sawicki KT, Sala V, Prever L, et al. Preventing and treating anthracycline cardiotoxicity: new insights. Annu Rev Pharmacol Toxicol. 2021;61(1):309–332. doi: 10.1146/annurev-pharmtox-030620-104842.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi: 10.1016/j.annonc.2019.10.023.
   PubMed Web of Science ®Google Scholar
• Jung HK, Park S, Kim NW, et al. Development of second primary cancer in korean breast cancer survivors. Ann Surg Treat Res. 2017;93(6):287–292. doi: 10.4174/astr.2017.93.6.287.
   PubMed Web of Science ®Google Scholar
• Payne DL, Nohria A. Prevention of chemotherapy induced cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398–403. doi: 10.1007/s11897-017-0353-9.
   PubMedGoogle Scholar
• Armenian S, Bhatia S. Predicting and preventing Anthracycline-Related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38(38):3–12. doi: 10.1200/EDBK_100015.
   PubMedGoogle Scholar
• van Dalen EC, Pal HJH, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016;2020(6):CD005008.
   Google Scholar
• Antman K, Suit H, Amato D, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol. 1984;2(6):601–608. doi: 10.1200/JCO.1984.2.6.601.
   PubMed Web of Science ®Google Scholar